Urology Times staff

John Myrga, MD, discusses recent findings on levels of pain, anxiety, and embarrassment for patients undergoing a prostate biopsy with a transperineal approach versus a transrectal approach.

Rana McKay, MD, says the CheckMate-214, KEYNOTE-426, CheckMate-9ER, and CLEAR trials have revolutionized the first-line treatment paradigm in advanced renal cell carcinoma.

“We wanted to help provide an understanding of what factors guide patient choice of third line therapy for overactive bladder,” says Anjali Kapur, MD.

Richard S. Matulewicz, MD, MSCI, MS, discusses the findings from his recent study that looked at patient knowledge about the link between smoking and bladder cancer.

In this installment of Urology Times’ 50th Anniversary Innovation Celebration, Bradley Gill, MD, MS, discusses the impact that the new wave of minimally invasive BPH treatments has had for both patients and urologists.

“For practicing urologists, I think it's important for us to recognize that when it comes to these techniques, even with Rezum, there's a variety of ways of doing them," says Bilal Chughtai, MD.

Jeffrey Tosoian, MD, MPH, recaps recent updates from the TheraP, ARAMIS, TITAN, ARASENS, and ATLAS prostate cancer trials.

“Once you get involved, more things pop up, and it’s a lot of fun. You meet a lot of interesting people and get a lot of great experiences,” says Daniel Igel, MD.

“It’s pretty clear that over the past 50 years we've seen innovations in BPH treatment both from the utilization of technology and also from the patient outcome and experience standpoint,” says Bradley Gill, MD, MS.

“We have helped developed policies at the national level as far as parental leave for residents and fellows, helping to streamline a lot of that process with the American Board of Urology,” says Daniel Igel, MD.

Illuccix is indicated for use in patients with suspected metastasis who are candidates for initial definitive therapy, or in patients with suspected recurrence based on elevated PSA level.

“We found that the adverse event rates have dropped dramatically, to about a third of what it was reported in the pivotal trial, but at the same time still had the same net benefits in terms of efficacy when it comes to Q max, symptomatic improvement, as well as PVR," said Bilal Chughtai, MD.

Physician Coach Support is a free resource that provides confidential, one-on-one peer support for clinicians.

“You do need to be a little bit careful because of the risk of priapism,” says Joshua A. Broghammer, MD.

Study authors found a rise in public interest in vasectomies, “particularly in states where abortion is or is expected to be prohibited.”

“I think that we’re going to see more and more advances in how we use mpMRI from a pre-treatment planning perspective,” William P. Parker, MD.

“Even though this is a really large study, and it appears that vitamin D may not be a sole contributor to improving urinary incontinence or overactive bladder, there may be a subgroup of men who could potentially respond,” says Alayne Markland, DO.

Eric S. Rovner, MD, discusses the use of bulking agents for stress urinary incontinence.

"Bulking agents changed the paradigm of stress urinary incontinence treatment considerably," says Eric S. Rovner, MD.

“One of the first pieces of advice I would give is to make sure you have the OR space available for the equipment,” says Jennifer A. Linehan, MD.

William P. Parker, MD, discusses the initial use of MRI and emergence of multiparametric MRI in the prostate cancer paradigm.

Joshua A. Broghammer, MD, discusses the development and use of intracavernosal injections for the treatment of patients with erectile dysfunction.

Stephanie Berg, MD, highlights the key findings of the PEACE-1 and ARASENS trials in patients with metastatic castration-sensitive prostate cancer.

“From a screening perspective, mpMRI really has changed how we evaluate men at risk for prostate cancer. It has improved the selection of men for biopsy and certainly improved our diagnostic rates,” says William P. Parker, MD.

Helen Heng-Shan Moon, MD, reflects on major advances in prostate cancer over the past 10 years and unmet needs that remain.

Christopher Wee, MD, discusses available androgen receptor inhibitors and unmet needs regarding the optimal use of these agents for patients with nonmetastatic castration-resistant prostate cancer.

“We did not happen to find that vitamin D compared to placebo lowered the odds of having incontinence at year 2 or year 5. Nor did it lower the odds of having overactive bladder symptoms at year 5,” says Alayne Markland, DO.

“I think my definition of who is the ideal patient has changed over the last 4 years,” says Jennifer A. Linehan, MD.

“We really need to be thoughtful about how our treatment recommendations may induce financial toxicity in patients with advanced prostate cancer,” says Daniel D. Joyce, MD.

“I feel like [HIFU] provided patients this intermediary treatment option…It was less invasive than radiation and surgery, but still provided cancer control, or at least for some patients delayed the time until they needed a more radical treatment,” says Jennifer A. Linehan, MD.